Indoco's Rs 65 Cr profit is all one-off: Ophthalmic sale gain masks an operating loss

Indoco Remedies reported consolidated PAT of Rs 65.44 Cr for Q1 FY27, swinging from a Rs 36.35 Cr loss a year ago and a Rs 23.68 Cr loss last quarter. But the profit is optical: it rests entirely on a Rs 97.34 Cr exceptional gain from the slump sale of the Ophthalmic division to Sunways (India). Strip it out and the group was still in the red — a pre-tax loss before exceptional of Rs 19.62 Cr, versus a Rs 36.66 Cr operating loss a year ago. The honest read is a narrowing operating loss dressed up as a headline profit, not a genuine turnaround.

Revenue rose ~6.8% YoY to Rs 467.5 Cr (down 1.7% sequentially). Growth was domestic-led — India sales up 12% to Rs 311.8 Cr — while international formulations were flat at Rs 154.5 Cr (+0.9%), falling short of management's prior-call guidance of "strong" international growth; MD Aditi Panandikar's own press-release commentary conceded the international formulations and API businesses only made "steady progress" and credited the quarter to the "resilient Domestic Formulation business." Margins did improve — standalone EBITDA/net-sales rose to 10.3% from 3.8%, and consolidated OPM roughly doubled to ~9% — consistent with the Europe manufacturing upgrades management flagged. But finance costs (Rs 28.3 Cr) and depreciation (Rs 34.5 Cr) still swamp operating profit, keeping the group below breakeven ex-divestment.

The stock went into the print at ₹261.97, up 11.9% over the past month of trading.

For context: this is the highest quarterly PAT in the last 6 quarters on our records; PAT has now risen for 2 consecutive quarters.

Standalone PAT Rs 82.32 Cr (EPS Rs 8.92) — consolidated EPS Rs 7.09; tax Rs 12.28 Cr, largely on the divestment gain

The quarter carried several corporate actions — completion of the Ophthalmic transfer (the source of the one-off), EU-GMP certification at Baddi Plant III and a Malta MA audit clearance at the Goa plant — that support the export thesis but did not yet show in international revenue. No formal quarterly street consensus exists for this smallcap; SMIFS (Jun 2026) models FY27 revenue +12.7% and adjusted PAT turning positive to ~Rs 16.7 Cr from an FY26 adjusted loss. Auditors flagged an Emphasis of Matter on subsidiary FPP Holding LLC's negative net worth and going-concern uncertainty. The question into H2 is whether core operations reach breakeven once the divested Ophthalmic revenue rolls out of the comparison base.